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Abstract
Background: Human African Trypanosomiasis threatens human health across Africa. The subspecies T.b. gambiense
is responsible for the vast majority of reported HAT cases. Over the past decade, expanded control efforts
accomplished a substantial reduction in HAT transmission, spurring the WHO to include Gambian HAT on its
roadmap for 2020 elimination. To inform the implementation of this elimination goal, we evaluated the likelihood
that current control interventions will achieve the 2020 target in Boffa prefecture in Guinea, which has one of the
highest prevalences for HAT in the country, and where vector control measures have been implemented in
combination with the traditional screen and treat strategy.
Methods: We developed a three-species mathematical model of HAT and used a Bayesian melding approach to
calibrate the model to epidemiological and entomological data from Boffa. From the calibrated model, we
generated the probabilistic predictions regarding the likelihood that the current HAT control programs could
achieve elimination by 2020 in Boffa.
Results: Our model projections indicate that if annual vector control is implemented in combination with annual or
biennial active case detection and treatment, the probability of eliminating HAT as public health problem in Boffa by
2020 is over 90%. Annual implementation of vector control alone has a significant impact but a decreased chance of
reaching the objective (77%). However, if the ongoing control efforts are interrupted, HAT will continue to remain a
public health problem. In the presence of a non-human animal transmission reservoir, intervention strategies must be
maintained at high coverage, even after 2020 elimination, to prevent HAT reemerging as a public health problem.
Conclusions: Complementing active screening and treatment with vector control has the potential to achieve the
elimination target before 2020 in the Boffa focus. However, surveillance must continue after elimination to prevent
reemergence.
Keywords: Human African trypanosomiasis, Active surveillance, Vector control, Disease elimination, WHO 2020 goals,
Tsetse target, Mathematical model
Background
Human African Trypanosomiasis (HAT) poses a serious
health risk to humans in vast regions of Sub-Saharan Africa
[1]. Gambian HAT disease progresses over several years
from the initial symptoms of fever, headaches and lymph-
adenopathy (Stage I) through neuropsychiatric disorders
and sleep disturbance (hence the name sleeping sickness)
(Stage II). If untreated, most HATcases result in death [1].
The two protozoan subspecies of the parasite Trypano-
soma brucei (T.b.) responsible, T.b. gambiense (Tbg) and
T.b. rhodesiense (Tbr), are both transmitted by tsetse
flies [1, 2]. Tbg causes the Gambian form of the disease
and is found in 24 countries across West and Central Af-
rica. Tbg accounts for over 95 % of HAT cases in Sub-
Saharan Africa [3–5]. It is transmitted by the Palpalis-
group of tsetse, particularly by the subspecies of Glossina
fuscipes and Glossina palpalis [6, 7]. Palpalis tsetse are
riverine insects and generally infest humid habitats on the
fringes of rivers, lake shores and wetlands of West and
Central Africa [8, 9]. Due to the absence of a vaccine,
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intervention strategies against HAT are based on on vec-
tor control as well as on “active” and “passive” case detec-
tion followed by treatment [7]. Active case detection is
implemented by HAT screening of an exposed population,
whereas passive case detection relies on self-presentation
of HAT patients. After widespread intervention cam-
paigns, the Gambian disease was nearly eradicated in the
early 1960s [1, 10]. However, a collapse of surveillance and
control activities, often due to periods of political instabil-
ity, led to disease rebound during the 1990s [11]. With
renewed control activities that centered around case de-
tection and treatment, the number of reported cases of
Gambian HAT fell by 75 % between 1999 and 2010, from
27,862 to 6,984 [4]. This decline in incidence has spurred
the WHO to include Gambian HAT on its 2020 roadmap
for the elimination of neglected tropical diseases [5]. The
WHO 2020 HAT elimination goal seeks to eliminate
Gambian HAT as a public health problem by reducing the
annual incidence rate to less than 1 in 10,000 people in
90 % of endemic foci [5]. It is unclear if the WHO HAT
elimination goal is feasible under current interventions or
if complementary strategies will have to be considered.
We developed a mathematical model for HAT to assess
the likelihood that ongoing vector control, active screen-
ing and treatment strategies could eliminate Gambian
HAT as a public health problem by 2020. We focus on the
Boffa prefecture in Guinea as our study area, which has
one of the highest prevalence for HAT in Guinea [12–14].
We fitted our model to HAT infection prevalence between
2008 and 2013 in Boffa East using a Bayesian inference ap-
proach to capture uncertainty of epidemiological data into
model projections. We used scenario analysis to evaluate
the robustness of our predictions to the existence of a
non-human animal transmission reservoir.
Methods
Model
Gambian HAT is generally regarded as a disease primar-
ily infecting humans, with uncertainty about the role of
non-human animals in sustaining the transmission cycle.
We developed two mathematical models, with and with-
out a non-human animal transmission reservoir. Here,
we describe the model that includes the non-human res-
ervoir reservoir. To evaluate the long-term effectiveness
of HAT control measures in Guinea, we developed a
three-species SEIR differential-equation model for T.b.
gambiense infection among tsetse (V), humans (H) and
non-human animals (NHA) (L) based on previous math-
ematical models [15, 16]. Each species was categorized
in terms of their infection status: susceptible (VS,HS, LS),
exposed (VE,HE, LE), infectious (VI,HI, LI) or recovered
(VR,HR, LR) (Fig. 1, Additional file 1). To capture the
reality that tsetse flies are more likely to become infected
during their first bloodmeal and the susceptibility of
tsetse to trypanosome decreases with age (hours after
eclosion of the fly from the puparium) at first meal [17],
Fig. 1 Model diagram of epidemiological compartments (circles) with rates of movement between each compartment (arrows). Further details
are presented in the Methods
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we assumed that tsetse are susceptible to trypanosome
infection only during their first blood-meal and within
24 h after emergence from pupa (VP) to the adult stage
(VS) [17]. Susceptible tsetse (VS) become infected after
feeding on an infectious human or NHA and enter the
exposed state (VE) during which the infection incubates.
After incubation, tsetse become infectious (VI) for the
rest of their life and can transmit infection to human
and non-human animals. We assumed that the tsetse
population has a density-dependent mortality rate:
μV ¼ μV 0 1þ μV 1V
 
; ð1Þ
where μV 0 is the death rate in the absence of intra-species
competition, μV 1 measures the effect of intra-species com-
petition on death rate, and V is the population size of all
non-pupal tsetse.
Both humans and NHAs may become exposed to in-
fection after being bitten by an infectious tsetse (VI).
After the incubation period, humans and NHA hosts
enter the infectious stage of HAT (HI1 and LI respect-
ively), in which they can transmit infection to susceptible
tsetse if bitten. Human hosts progress to stage II of
infection HI2ð Þ , in which they are assumed not to be
infectious due to isolation arising from the severity of
symptoms in this stage of disease progression [1, 18].
Infected people in stage II either seek treatment and
recover (HR) or die due to being untreated or due to
treatment failure. Successfully treated HAT patients are
temporarily resistant to reinfection and exposure via tse-
tse (through immunity to reinfection or hospitalization,
respectively) before returning to full susceptibility (HS).
Infectious NHAs (LI) clear infection and become tem-
porarily immune to reinfection (LR) before returning to
the susceptible state (LS). We assumed that both human
and NHA populations are of constant size throughout
the analysis.
Our model captured the annual active screening and
treatment in Boffa, by assuming that active surveillance
occurs within a 20 day-period, during which a propor-
tion, ϕ, of the human population is tested for Tbg using
the Card Agglutination Test for Trypanosomiasis
(CATT) and then a Trypanolysis test (TL). While the
CATT diagnostic tool can be performed in situ using
blood from a finger prick, TL is performed in laborator-
ies using plasma samples [19]. TL has been implemented
successfully in Guinea, Cote d’Ivoire and Burkina Faso
during medical surveys with a 100 % specificity, com-
pared to 91 % for CATT [20]. Therefore the combined
CATT-TL testing has a sensitivity of ρ and specificity of
100 %. Once infection status has been confirmed, a
lumbar puncture is performed to determine whether the
patient has progressed to stage II. We assumed that all
patients testing positive were treated [21], such that a
fraction, ϕρϵ1 and ϕρϵ2, of stage I and stage II HAT
patients recover after 20 days of active surveillance
(where ϵ1 and ϵ2 are the efficacies of stage I and stage II
treatment).
To reduce transmission, insecticide-treated targets
have been deployed in areas where people live and work
[21]. Consistent with previous model calibration work
[22] that showed temporary efficacy of this type of vec-
tor control, we assumed that for the initial three months
of deployment, the targets induced a tsetse maximal kill
rate of x, which decreased linearly to zero in the following
three months, and remained ineffective for the subsequent
six months until the targets were replaced [22].
Data sources
To calibrate and validate our dynamic model, we used
multiple data sources from the Boffa region of Guinea.
For calibration, we used four data sources: i) the number
of HAT cases (partitioned by stage) diagnosed and treated
in the Boffa East region through active annual screening
activities in 2008 and 2013 with known coverage [12, 21],
ii) the Tbg prevalence in non-human animal reservoir
across Boffa East, iii) the Tbg prevalence in tsetse across
Boffa East, and iv) the reduction in tsetse density between
2012 and 2013 in Boffa East as a result of a vector control
program. For validation, we used i) the number of HAT
cases (partitioned by stage) diagnosed and treated in Boffa
East through active annual screening activities in 2010
and 2012 [12, 21], and ii) the HAT incidence in 2012 [21].
To parameterize human population size, we used data
from a 2011 census of Boffa. As previous a study has
shown Tbg prevalence to be extremely low in tsetse and
NHA [12], we assumed that both of these prevalences
were under 1 %. All other parameters were based on pub-
lished estimates (Table 2).
Model fitting
To estimate posterior distributions for the unknown epi-
demiological parameters—probability of tsetse bite on
humans (βVH), transmission probability from tsetse to
humans (βH), treatment seeking rate of stage II patients
(ζ) and transmission probability from tsetse to NHA
(βL)—we used a Bayesian melding method [23, 24] to
calibrate the model to prevalence data for stage I and
stage II HAT cases in Boffa East Mainland in 2008, as
well as Trypanosomiasis prevalence among tsetse and
the NHA reservoir [12, 21]. Given that there was no ac-
tive screening or vector control in Boffa between 2000
and 2008, we assumed an equilibrium prevalence prior
to 2008. We modeled the active screening with case
treatment in 2008, 2010, and 2012 across Boffa East
with the observed 10.2 %, 31.2 %, and 53.4 % coverage re-
spectively. The deployment of vector control through
insecticide-treated targets in 2012 decreased tsetse density
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by 60 % over a year [21]. To estimate the maximal kill rate,
x, we used maximum likelihood estimation with normal
distribution as the likelihood function to fit the model to
this reduction in tsetse density [21]. The model was run
until 2013 for best fit parameters from Bayesian fitting
with active screening and treatment in year 2008, 2010,
2012 followed by vector control in year 2012. We refined
the posterior distributions of the epidemiological parame-
ters (βVH, βH, ζ , βL), obtained from the initial Bayesian
fitting of the model to the 2008 data which were then used
as prior distributions for fitting the model to 2013 data of
HAT stage I and II prevalences (Fig. 2).
The Bayesian melding method takes all available prior
information on model inputs and, when combined with
a likelihood function, generates posterior distributions of
model parameters and predicted model outputs through
statistical comparisons of model predictions with obser-
ved data. We used a uniform prior distribution for each
model parameter (βVH, βH, ζ, βL) and Beta distributions
for the observed data on stage I and stage II HAT, tsetse
and NHA trypanosomiasis prevalence. To describe the
Bayesian melding algorithm, we denote the simulation
model (Additional file 1) by M, the epidemiological pa-
rameters (βVH, βH, ζ, βL) as Θ and the model-predicted
output as Γ =M(Θ). We denote the prior distribution for
each model parameter as q(Θ). We denote the data as W
and the associated likelihood of the model outputs as
L(Γ) = Pr (Γ|W). The posterior distribution of inputs
is then proportional to q(Θ)L(Γ). We implemented a
sample-importance-resample algorithm to approximate
the posterior distribution. First, we generated a set of
input parameters, Θ(i), by randomly sampling from
the respective prior distributions i times. We then evalu-
ated the model using that set of parameters, Γ(i) =M(Θ(i))
for each run i. Next, we calculated the corresponding
likelihood for the model run. For each sample Θ(j),
with non-zero corresponding likelihood, the sampling
weight was Ω jð Þ ¼ L Γ jð Þð Þ=
XNl
k¼1
L Γ kð Þð Þ. To ensure a
sufficient sample from the posterior distributions, we
set i = 400,000.
The number of non-zero likelihood samples, Nl, was
520 for the model without NHA reservoir, and 1,053 for
the model with an NHA when fit to 2008 prevalence
data. After refinement to fit the models to 2013 data, the
final sample size was 290 for the model without an
NHA reservoir, and 395 with an NHA reservoir. We
Fig. 2 Model fits (a) base-case model without a non-human animal (NHA) reservoir, and (b) model with an NHA reservoir. Trajectories of the
model fitted to prevalence data for stage I and stage II HAT cases from Boffa East mainland using Bayesian melding for years 2008 and 2013 and
validated using 2010 and 2012. The red lines represent the HAT phase I and phase II prevalence estimated by our model for baseline epidemiological
parameters (the grey areas represent the 95 % confidence intervals)
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repeated this sampling procedure 10,000 times with re-
placement, using a probability of selection proportional
to the sampling weights to obtain an approximation of
the posterior distribution for the inputs. Output from
the simulation resampled most frequently (i.e., the simu-
lation most compatible with empirical prevalence data)
represents the estimated mode for the output parame-
ters of interest. The 2.5th and 97.5th percentiles of the
inputs (and corresponding model outputs) correspond
to 95 % credible limits.
Effectiveness of intervention strategies
We evaluated the disease dynamics under two model
structures: first, with no NHA reservoir, following a sur-
vey in Boffa showing no evidence of NHA infection [12],
and second, with a small prevalence of NHA infection,
following studies suggesting the importance of NHAs in
the maintenance of disease transmission [25]. Using the
calibrated models, we projected the model between 2013
and 2030 under the assumption that all control mea-
sures are implemented with the same coverage and effi-
cacies as achieved in year 2012, with the exception of
years 2014 and 2015 when no control measures were
implemented due to the Ebola crisis. We then evaluated
the probability of reaching the WHO elimination thresh-
old of less than one case per 10,000 annually, which
corresponds to a “low transmission focus”, and also the
more stringent condition of 1 case per 100,000 inhabi-
tants, which corresponds to a “very low transmission
focus” [5]. We assessed the probability of elimination
under three different control interventions: annual vector
control effort, annual vector control effort with annual
active-screening and treatment, and annual vector control
effort with biennial active-screening and treatment.
Model code
The analysis was performed using Matlab R2014b, and all
model codes are available via https://github.com/abhiganit/
Sleeping-Sickness.
Results
We employed a Bayesian melding approach to fit our
models, with and without NHA reservoir, to epidemio-
logical data of HAT in Boffa East, Guinea. Using prior
distributions of epidemiological parameters based on
estimates available in the literature (Table 1), we derived
a posterior distribution for each epidemiological param-
eter for which the model gives the best estimate for
stage I and stage II HAT prevalences in 2008 and 2013
and trypanosomiasis prevalence among tsetse and NHA
reservoir (Fig. 2, Tables 2 and 3). The prevalence of stage
I and Stage II HAT in 2010 and 2012 and the stage I in-
cidence in 2013 were used for model validation (Fig. 2
and Table 3).
We projected the trajectory of our model until 2030
and estimated the probability of HAT elimination as a
public health problem by 2020 under various control in-
terventions (Fig. 3). Predictions from our model indicate
that if no further control intervention is implemented
after 2015, HAT will likely continue as a public health
problem in Boffa East with annual incidence exceeding 2
cases per 10,000 individuals by the end of 2020. To
evaluate the likelihood of achieving the WHO 2020 goal
of HAT elimination as a public health problem in Boffa,
we assumed that the intervention strategies are continu-
ously implemented from 2016 until 2020, at which time
control efforts are ceased. Our base-case model, without
NHA reservoir, showed that annual implementation of
vector control at the same efficacy as 2012 is likely to
eliminate HAT as a public health problem by 2020,
with the new cases remaining less 1 per 10,000 people
(Fig. 3a). If vector control is complemented by annual
active screening and treatment, then the model predicts
that a 100 % probability of elimination is achieved in 2018.
With only biennial implementation of active screening
and treatment, elimination is achieved in 2019 (Fig. 3a).
When we incorporated a non-human animal transmis-
sion reservoir, our model predicts at least 77 % probability
of HAT elimination as a public health problem in Boffa
East by 2020 under the three control strategies if the
coverage and efficacy remains consistent (Fig. 3b). Though
likelihood of elimination is high, none of the three control
strategies implemented at their 2012 efficacy level guaran-
tee elimination of HAT as it was the case in the absence
NHA reservoir (compare Fig. 3a to b). Moreover, in the
presence of an NHA reservoir, intervention strategies
must be maintained at high coverage, even after 2020
elimination, to prevent HAT reemerging as a public health
problem in Boffa East by 2025 (Fig. 3b).
Maintaining a high efficacy of vector control, high
density of insecticide-treated targets, may be unsustain-
able in the long term. Our results indicate that if vector
control efficacy is reduced by 25 %, this would lower the
probability of HAT elimination as a public health problem
by the end of 2020 to 77 %. Moreover, a 50 % reduction in
vector control efficacy would likely prevent elimination by
the target date, with only a 1.9 % probability of attaining
the goal (Fig. 4a).
In the presence of NHA reservoir, a reduction of vec-
tor control efficacy by 25 % would lower the probability
of HAT elimination as a public health problem by the
end of 2020 from 77 to 67 % (Fig. 4b). A 50 % reduction
in efficacy would lower the probability of HAT elimin-
ation to 49 % (Fig. 4b). If vector control is combined
with active screening and treatment, a 50 % reduction in
vector control efficacy and active screening coverage
achieves a 53 % probability of HAT elimination by 2020
for annual and biennial active screening, compared with
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16 % for biennial and 57 % for annual active screening
in the absence of an NHA reservoir (Fig. 4).
Considering that current control efforts are predicted
to be sufficiently efficacious to meet the WHO HAT
elimination goal in Boffa East Mainland, we evaluated
time to elimination under the more stringent criteria of
1 cases per 100,000 people when control interventions
are continuously implemented until 2030. We found that
vector control implemented annually will meet the
threshold if it is continued through 2023. If the annual
vector control is complemented with annual or biennial
active screening, the threshold can be achieved by the
end of 2020 and 2021, respectively (Fig. 5). We also
found that if the controls are implemented with lower
efficacy and coverage, the control will have to be con-
tinued at least until 2025 to meet the threshold
(Fig. 5).
We used Akaike Information Criterion (AIC) to
compare our base-case model and the model with an
NHA reservoir. The model without NHA had smaller
AIC. However, the relative likelihood for the model
with NHA was 27 % and the difference in AIC value
between the models was 2.64, suggesting that both
models are plausible [26]. Thus, while there is some
support for preferring the simpler model that includes
an NHA reservoir, there is limited evidence for either
the presence of absence of an NHA transmission
reservoir.
Table 1 Definitions and values for model parameters
Parameter Definition Value Reference
V/H Number of tsetse flies (V) per human (H) 17 [15]
L/H Number of NHA (L) per human (H) 1/6 [15]
H Population size of Boffa East Mainland in 2008 14,500 Unpublished data
BV Tsetse constant birth rate 0.05/day [15]
1/ηV Duration of pupae stage in tsetse 20 days [18]
μV0 Tsetse death rate without competition 0.030/day [15]
μV1 Death rate competition parameter 0.0002 Assumed
1/σV Susceptibility period in tsetse 1 day [15]
a Tsetse biting rate 0.333/day [15]
βVH Probability of tsetse bite on human See Table 2 Estimated
βVL Probability of tsetse bite on NHA min(1-βVH,0.71) [25]
1/τV Incubation period in tsetse 25 days [15]
μH Human constant death rate 4.66e-05 /day [34]
βH Transmission probability from tsetse to humans See Table 2 Estimated
1/τH Incubation period in humans 12 days [15]
1/γH1 Stage I infectious period without treatment 526 days [35]
1/γH2 Stage II infectious period without treatment 252 days [36]
1/δH Immune period in humans after treatment 50 days [15]
βL Transmission probability from tsetse to NHA See Table 2 Estimated
βV Transmission probability from humans/NHA to tsetse 0.2 [2, 15]
1/τL Incubation period in NHA 12 days [15]
1/γL Infectious period in NHA 50 days [15]
1/δL Immune period in NHA 50 days [15]
ϕ Coverage of active surveillance Varies -
ρ Probability that a HAT patients gets a positive
CATT and then a positive antibody/Trypanolysis test
0.87 [1]
ε1 Efficacy of stage I treatment (pentamidine) 0.94 [37]
ε2 Efficacy of stage II treatment (nifurtimox-eflornithine) 0.965 [38]
ζ Treatment seeking rate of stage II patients See Table 2 Estimated
p Probability of death due to stage II treatment
failure (nifurtimox-eflornithine)
0.007 [38]
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Discussion
We developed a mathematical model of HAT transmis-
sion calibrated to data from Boffa East in Guinea to
evaluate the effectiveness of vector control combined
with active screening to eliminate HAT as a public
health problem in this disease focus. Annual vector con-
trol combined with annual or biennial active screening
and treatment is predicted to achieve the WHO HAT
elimination goal by 2020 in Boffa East, if maintained at
the current efficacy. Vector control alone leads to at
least a 77 % probability of achieving the elimination goal.
If current control efficacies cannot be sustained, lower
probabilities of elimination by 2020 are predicted. In the
presence of a non-human animal reservoir, our model
predicts an increased risk of HAT reemerging as a public
health problem in Boffa East after 2025, if control efforts
are not continued after the public health elimination
goal is achieved in 2020.
While active screening and treatment has effectively
controlled HAT in many foci [27], some areas that have
not concomitantly adopted vector control have failed to
bring HAT under control [7]. There is also evidence to
suggest that there are asymptomatic carriers and sero-
positive cases who are not detected by parasitological
techniques, which will likely limit the effectiveness of
active screening and treatment for breaking the HAT
transmission cycle [25, 28, 29].
Consistent with a mathematical model fitted to data
from the Democratic Republic of Congo [39], our model
does not inform the question of whether there exists a
non-human animal reservoir. However, the existence of a
NHA reservoir impacts the chance of sustaining HAT
elimination. We found that, in the presence of a non-
human animal reservoir, HAT was more resistant to elim-
ination, with a heightened risk of becoming a public health
problem after 2020 again if control efforts are interrupted.
Moreover, when there is a NHA transmission reservoir,
using vector control strategies to complement HAT treat-
ment programs is crucial to achieve elimination.
The impact of control strategies in disease foci depends
on the trypanosomiasis prevalence among tsetse and NHA
reservoir. As the tsetse and NHA prevalence in Boffa is
relatively low [12], it may take longer to reach elimination
in higher intensity areas. For example, Rock et al. [39]
showed that HAT elimination in the high endemicity re-
gion of Democratic Republic of Congo is highly unlikely to
be reached by 2020 with current controls. Regardless, con-
trol efforts should be sustained following HAT elimination
as a public health problem, as the possibility of a NHA res-
ervoir poses a risk for reemergence, as would transmission
from surrounding regions. Although we assumed specific
ratios of human to tsetse and humans to NHA different ra-
tios would have a marginal impact on our results, as these
variations will be absorbed into the transmission parame-
ters that were fitted to prevalence data.
The data from medical surveys conducted in Guinea
use the Trypanolysis test (TL) to ensure accuracy of
HAT patient reporting. However, many countries rely on
CATT and, if positive, a parasitology test for confirm-
ation. As CATT has a relatively low specificity and a
parasitology test has a relatively low sensitivity, many
foci will suffer from under- or over-diagnosis, respect-
ively. Such misdiagnosis will implicitly lower or raise the
stringency of the elimination threshold, respectively.
Previous studies have suggested that tsetse may bite a
host more than once per feeding cycle, shortening the feed-
ing interval of tsetse flies to less than three days [30, 31]. A
shorter cycle increases the biting rate of tsetse, resulting
in a higher probability that an infected tsetse fly will infect
a susceptible host, and thus increasing the effectiveness of
vector control.
In our study, we assumed that tsetse feed randomly on
individuals in a given species, such that individuals are
equally likely to be bitten by tsetse, and thereby exposed
Table 3 Model calibration to tsetse and NHA trypanosome prevalence and validation to 2013 stage I HAT incidence
Data Estimates from base-case model (no NHA reservoir) Estimates from model with NHA
Tsetse prevalence (2008) Assumed < 1 % 0.0018 % (95 % CI:0.001–0.0040 %) 0.08 % (95 % CI:0.002–0.4 %)
NHA prevalence (2008) Assumed < 1 % Fixed at 0 % 0.3 % (95 % CI: 0.0005–0.9 %)
Stage I HAT incidence (2013) 0.07 % (95 % CI: 0.01–0.2 %) 0.15 % (95 % CI: 0.07–0.2 %) 0.17 % (95 % CI: 0.06–0.21 %)
Table 2 Prior and posterior distribution of parameter estimatesa
No non-human animal reservoir (Base-case)
Parameter Prior Median (95 % CI)
βVH U(0.1,0.6) 0.3750 (0.1698, 0.5626)
βH U(0,1) 0.1751 (0.0778,0.8550)
1/ζ U(0,252) 202 (97,250)
x - 0.0503
With non-human animal reservoir
Parameter Prior Median (95 % CI)
βVH U(0.1,0.6) 0.3020 (0.1021, 0.5932)
βH U(0,1) 0.0076 (0.0011,0.3265)
1/ζ U(0,252) 203 (101, 243)
βL U(0,1) 0.1345 (0.0476, 0.6619)
x - 0.0503
aLikelihood function was formed using beta distributions for stage I and stage
II HAT cases in year 2008 (Stage I: Beta(3,1488), Stage II: Beta(2,1488) and in
year 2013 (Stage I: Beta(3,7788), Stage II: Beta(4,7788)
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Fig. 4 Probabilities of HAT elimination as public health problem by the end of 2020 (a) in the absence of a non-human animal (NHA) reservoir, and (b)
with an NHA reservoir. All controls were implemented either annually or biennially and different colors represent different reduction levels of vector
control efficacy and active screening coverage relative to 2012 efficacy and coverage
Fig. 3 Probability of HAT elimination as public health problem under various control strategies (a) in absence of a non-human animal (NHA) reservoir,
and (b) with an NHA reservoir. Vector control and active screening and treatment are implemented with the 2012 efficacy and coverage
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to trypanosomiasis. However, empirical studies have ob-
served heterogeneity in exposure to tsetse bites within
humans and livestock [21, 32]. Within-species heterogeneity
suggests that either tsetse flies may be preferentially feeding
on certain individuals within a given species or that some in-
dividuals are geographically more exposed to tsetse habitats.
Notwithstanding variation in tsetse bite exposure, some
individuals may be more genetically susceptible to HAT in-
fection [28], which could impact elimination goals. For ex-
ample, a reservoir of undiagnosed cases who maintain a
transmission reservoir will truncate the effectiveness of case
finding and treatment. Similarly, clustering of incidence in
remote sub-populations will also limit the effectiveness of
human-targeted control interventions. Heterogeneities in
tsetse exposure would be important to explore in future
work assessing the sustainability of HAT elimination [21].
Given that tsetse population sizes fluctuate seasonally
and vary between foci [15], human exposure to tsetse
and therefore HAT transmission dynamics may exhibit
seasonal and geographical variation [33]. Our model ac-
counts for the impact of seasonal variation on the effi-
cacy of insecticide-treated target traps using a relatively
simple step function to capture the decrease in traps ef-
ficacy over time from seasonal and non-seasonal factors.
With data from enhanced surveillance techniques across
wider areas, future modeling may be able to explicitly
incorporate seasonality in tsetse population dynamics
and human–tsetse contact.
Conclusion
We evaluated the feasibility of HAT elimination goal by
2020 in Boffa East focus using a data-driven mathematical
model by calculating probabilistic estimates of whether
the current HAT control program is likely to achieve HAT
elimination as a public health problem by 2020. Our ana-
lysis revealed that combinations of annual vector control
with active-screening will most likely meet the WHO
2020 elimination goal. Furthermore, the combined control
implemented with the coverage and efficacy achieved in
2012 is predicted to be sufficient to reduce incidence
below 1 case per 100,000 people by 2020. As vector con-
trol works synergistically with active screening and treat-
ment, using a combined approach for Boffa has the
potential to meet the WHO goal by 2020 in Boffa focus.
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